Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety disorder, and migraines.
Lead Product(s): Lamotrigine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Eversana
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2022
Details:
Aquistion covers the lead products include the branded generics Cital® and Lamotrix® (lamotrigine), both relevant brands in their respective markets. With branded generics commanding the dominant share of market, Poland has the highest penetration of generics in Europe.
Lead Product(s): Lamotrigine
Therapeutic Area: Neurology Product Name: Lamotrix
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Neuraxpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 25, 2020
